481 related articles for article (PubMed ID: 3545453)
1. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
2. Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways.
Hudson MA; Brown EJ; Ritchey JK; Ratliff TL
Cancer Res; 1991 Jul; 51(14):3726-32. PubMed ID: 2065329
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
[TBL] [Abstract][Full Text] [Related]
4. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
5. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
6. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
Ratliff TL; Kavoussi LR; Catalona WJ
J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931
[TBL] [Abstract][Full Text] [Related]
7. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
8. [Enhancement of bacillus Calmette-Guerin attachment to the bladder wall: experimental study].
Shen Z; Ding G; Chen Z
Zhonghua Wai Ke Za Zhi; 2001 Dec; 39(12):951-3. PubMed ID: 16201181
[TBL] [Abstract][Full Text] [Related]
9. [Attachment of bacillus Calmette-Guerin to bladder cancer cells and the expression of interleukin-6 biological activity].
Zhong H; Gu F; Yu L
Zhonghua Wai Ke Za Zhi; 1995 Feb; 33(2):119-22. PubMed ID: 7656701
[TBL] [Abstract][Full Text] [Related]
10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
11. Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin.
Shapiro A; Kelley DR; Oakley DM; Catalona WJ; Ratliff TL
Cancer Res; 1984 Jul; 44(7):3051-4. PubMed ID: 6373001
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria.
Hudson MA; Ritchey JK; Catalona WJ; Brown EJ; Ratliff TL
Cancer Res; 1990 Jul; 50(13):3843-7. PubMed ID: 2191767
[TBL] [Abstract][Full Text] [Related]
13. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
14. Study on enhancement of fibronectin-mediated bacillus Calmette-Guérin attachment to urinary bladder wall in rabbits.
Shen ZJ; Wang Y; Ding GQ; Pan CW; Zheng RM
World J Urol; 2007 Oct; 25(5):525-9. PubMed ID: 17665201
[TBL] [Abstract][Full Text] [Related]
15. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
16. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.
Schneider B; Thanhäuser A; Jocham D; Loppnow H; Vollmer E; Galle J; Flad HD; Ulmer AJ; Böhle A
World J Urol; 1994; 12(6):337-44. PubMed ID: 7881473
[TBL] [Abstract][Full Text] [Related]
17. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity.
Zhao W; Schorey JS; Bong-Mastek M; Ritchey J; Brown EJ; Ratliff TL
Int J Cancer; 2000 Apr; 86(1):83-8. PubMed ID: 10728599
[TBL] [Abstract][Full Text] [Related]
18. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
